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Abstract
Background: Stress urinary incontinence (SUI) is a prevalent and costly condition which may be treated
surgically or by physical therapy. The aim of this review was to systematically assess the literature and
present the best available evidence for the efficacy and effectiveness of pelvic floor muscle training (PFMT)
performed alone and together with adjunctive therapies (eg biofeedback, electrical stimulation, vaginal
cones) for the treatment of female SUI.
Methods: All major electronic sources of relevant information were systematically searched to identify
peer-reviewed English language abstracts or papers published between 1995 and 2005. Randomised
controlled trials (RCTs) and other study designs eg non-randomised trials, cohort studies, case series,
were considered for this review in order to source all the available evidence relevant to clinical practice.
Studies of adult women with a urodynamic or clinical diagnosis of SUI were eligible for inclusion. Excluded
were studies of women who were pregnant, immediately post-partum or with a diagnosis of mixed or urge
incontinence. Studies with a PFMT protocol alone and in combination with adjunctive physical therapies
were considered.
Two independent reviewers assessed the eligibility of each study, its level of evidence and the
methodological quality. Due to the heterogeneity of study designs, the results are presented in narrative
format.
Results: Twenty four studies, including 17 RCTs and seven non-RCTs, met the inclusion criteria. The
methodological quality of the studies varied but lower quality scores did not necessarily indicate studies
from lower levels of evidence. This review found consistent evidence from a number of high quality RCTs
that PFMT alone and in combination with adjunctive therapies is effective treatment for women with SUI
with rates of 'cure' and 'cure/improvement' up to 73% and 97% respectively. The contribution of adjunctive
therapies is unclear and there is limited evidence about treatment outcomes in primary care settings.
Conclusion: There is strong evidence for the efficacy of physical therapy for the treatment for SUI in
women but further high quality studies are needed to evaluate the optimal treatment programs and
training protocols in subgroups of women and their effectiveness in clinical practice.
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Background
Aim
The aim of this review was to critically appraise relevant
peer-reviewed reports of original investigations of the effi-
cacy or effectiveness of pelvic floor muscle training
(PFMT) performed alone and together with other adjunc-
tive physical therapies (eg biofeedback, electrical stimula-
tion, vaginal cones) for stress urinary incontinence in
women published in the last decade (1995–2005).
Background and rationale
The International Continence Society defines urinary
incontinence (UI) as the complaint of any involuntary
leakage of urine [1]. It is a widespread [2] and prevalent
condition affecting an estimated 1.8 million community-
dwelling women over the age of 18 years in Australia [3].
The personal financial costs for women managing UI in
Australia in 1998 were estimated at A$372 million per
annum and the total annual costs of treatment at A$339
million [4].
Stress and urge incontinence are the two most common
types of UI, which co-exist as mixed incontinence. Urine
leakage is classified according to what is reported by the
woman (symptoms), what is observed by a clinician
(signs) and on the basis of urodynamic studies. Stress uri-
nary incontinence (SUI) is the complaint of involuntary
leakage on effort or exertion, sneezing or coughing (symp-
tom) or the observation of urine leakage at the same time
as the exertion (sign). SUI is the most common type of UI.
Urge urinary incontinence (UUI) is the complaint of
involuntary leakage accompanied or immediately pre-
ceded by, urgency [1]. Both are amenable to conservative
therapy but surgery has conventionally been offered for
SUI and medication with behavioural methods for UUI.
The efficacy of surgery is variable [5-7]. Pharmacotherapy
for SUI has also been developed but not extensively pre-
scribed [8]. Since 1992, conservative management of UI
has been promoted by the US Department of Health and
Human Services (AHCPER) as first-line treatment for SUI
for its efficacy, low cost and low risk [9].
SUI occurs when intra-vesical pressure exceeds urethral
closure pressure in the absence of a detrusor contraction.
SUI may be due to bladder neck hyper-mobility or poor
urethral closure pressure [1]. The pelvic floor muscles
(PFM) function to elevate the bladder, preventing descent
of the bladder neck during rises in intra-abdominal pres-
sure and to occlude the urethra. The theoretical basis for
physical therapy to treat SUI is to improve PFM function
by increasing strength, coordination, speed and endur-
ance [10] in order to maintain an elevated position of
bladder neck during raised intra-abdominal pressure with
adequate urethral closure force [11].
A distinction is to be made between the terms 'efficacy'
and 'effectiveness'. Efficacy is defined as "the probability
of benefit to individuals in a defined population from a
medical technology applied for a given medical problem
under ideal conditions of use". By contrast, effectiveness is
considered to have all the attributes of efficacy but to
reflect "performance under ordinary conditions by the
average practitioner for the typical patient" [12].
Pelvic floor muscle training (PFMT) and other physical
therapies for the treatment of female SUI [13] and UI [14-
16] has been the subject of previous systematic reviews.
All of these reviews limited their inclusion criteria to ran-
domized controlled trials, because this type of study
design is considered to provide the best evidence of effi-
cacy for an intervention by attempting to minimize biases
and confounding variables [17].
Because of the very rigor of an RCT, it may not necessarily
be appropriate to generalise the results of such a carefully
controlled trial into clinical practice. Thus a treatment
modality with demonstrated efficacy in an RCT may not
be effective when combined with other modalities for a
different patient population in clinical practice
[12,18,19]. Subjects for RCTs are selected according to
strict and often limited criteria, health personnel are
highly trained and a standardized intervention is applied
to all subjects, regardless of individual subject characteris-
tics and clinical presentations (eg severity of incontinence,
PFM function (strength, endurance, awareness)[20,21]. In
clinical practice, physiotherapists are trained to provide
treatment based on individual assessment and clinically
reasoned processes, for patients presenting with inconti-
nence and with a range of co-morbidities. Thus different
treatment modalities (adjunctive therapies) may be
applied to individual patients in conjunction with PFMT
in order to activate a weak muscle, to improve sensory
feedback, to enhance patient cooperation and compliance
with an exercise program [22]. Observational studies pro-
vide the opportunity to establish the effectiveness of such
interventions in routine clinical practice [19]. This is diffi-
cult to achieve in randomized trials [19] other than prag-
matic randomized trials [23].
The effectiveness of physical therapy in clinical practice
may thus be assessed from the evidence from lower level
studies i.e. levels III & IV according to the Australian
National Health and Medical Research Council's hierar-
chy of evidence [24]. These studies would be more likely
to report on cohorts or case series of patients, treated
under typical clinical conditions. In addition, such studies
could also provide other information about clinical prac-
tice, such as the responsiveness to treatment (length of
time taken to respond) not otherwise available from an
RCT. No systematic review on SUI has reported on theBMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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generalisability (external validity) of the study findings
and their applicability in clinical practice. External validity
is an important aspect of methodological quality, but
there are few critical review tools to evaluate whether the
procedures, hospital characteristics and patient samples
reported in the literature are relevant to clinical practice
[25].
Objective
This systematic literature review evaluated the evidence
for the efficacy and effectiveness of physical therapy,
described as pelvic floor muscle training with, and with-
out, adjunctive physical therapies such as biofeedback,
electrical stimulation or vaginal weights for the treatment
of SUI in women.
The review addressed the following research questions:
1. What is the evidence for PFMT, either alone or in com-
bination with adjunctive therapies, when considering all
treatment protocols, for the treatment for SUI in women,
in the short and medium terms (up to 12 months after
treatment)?
2. What is the evidence for different types of PFMT?
3. What other reported factors could affect outcome of
physical therapy?
4. What is the optimal period of treatment and number of
treatments?
5. What is the effectiveness of physical therapy in clinical
practice settings and can the findings in the research set-
tings be generalised to clinical practice?
Methods
Criteria for inclusion in this review
The methods for conducting this systematic review and
for assessing the quality of the evidence are based on the
processes outlined by the Joanna Briggs Institute [26] and
the Centre for Reviews and Dissemination at the Univer-
sity of York [21].
Types of studies
In order to better understand whether those interventions
which have demonstrated efficacy in the research setting
are also effective when applied in the clinical setting, pro-
spective research designs other than RCTs were also con-
sidered in this review. These included quasi-experimental,
controlled clinical trials, observational studies and case
studies/series. It was anticipated that these types of
research designs may provide information about patient
populations more typical of those encountered in primary
care settings eg with a broad range of inclusion criteria.
This information is needed to underpin estimates of the
costs of treatment in the primary care setting.
In this review, experimental studies were classified as
RCTs when randomly allocated intervention groups were
compared, where a distinct control group could receive
either another treatment modality or 'no treatment'. Thus
studies were eligible for inclusion if there was at least one
arm with a PFMT protocol, alone or together with other
adjunctive therapies, compared with either a control
group of 'no treatment' or 'usual treatment' or a different
PFMT protocol, alone or together with other adjunctive
therapies (biofeedback, electrical stimulation or vaginal
weights).
Study designs without a control group but with a PFMT
protocol, alone or together with other adjunctive thera-
pies were also included. Studies or arms of studies which
did not have a PFMT protocol and retrospective analyses
or audits, which were unlikely to provide robust evidence
of effectiveness because of time-based bias, were excluded.
Only peer-reviewed studies published in English in the
last decade (1995–2005) were included in this review.
The search was limited to the last decade in order to
source the most recent, high-quality evidence [27]. This
decision was justified on the grounds that systematic
reviews evaluating the earlier literature found many of the
included studies to be of poor or moderate methodologi-
cal quality [13-15] and based on the findings of Moseley
et al (2002), it was assumed that the more recent literature
was more likely to be of higher methodolgical quality.
Types of participants
The study populations considered in this review included
subjects who were adult females of any age, not pregnant
or within six weeks post-partum, with a clinical or urody-
namic diagnosis of SUI. Clinical diagnosis could be based
on the self-report (symptom) and/or sign of stress incon-
tinence. Studies were excluded if they included subjects
with mixed UI or detrusor overactivity because of the
assumption of a different underlying pathology and thus
rationale of treatment, even if outcomes for subgroups of
women with SUI were reported.
Types of interventions
Inclusions
Any PFMT i.e. pelvic floor muscle exercises, with applica-
tion of a specific training protocol or PFMT together with
any combination of adjunctive therapies: biofeedback
(BF), electrical stimulation (ES), vaginal weights or cones
(VW). All types of BF were included if it was used to
enhance the awareness of a correct PFM contraction: EMG
(electromyography, either vaginal or surface abdominal),
vaginal squeeze pressure or ultrasound. BiofeedbackBMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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could be used to enhance teaching of the correct response
or to train repetitive PFM contractions.
ES included any low or medium frequency current
applied externally (interferential currents) or internally
via a vaginal electrode.
Exclusions
Interventions that included any of the therapies listed
above as adjunctive, either alone or in combination, with-
out a PFMT protocol. Thus in studies which included a
subgroup which was treated with one or more adjunctive
therapies without a specific PFMT protocol, the results of
the subgroup were excluded from the analysis. Thus BF, ES
and VW were not considered on their own or together
unless they were part of program with a PFMT protocol.
Adjunctive therapies have been the subject of previous
reports [15,28].
Types of outcome measures
Only outcome measures relevant for clinical practice were
reported in this review, thus urodynamic study measures
were excluded.
The principal measures of effectiveness were considered to
be the proportion of women cured (continent/dry), and
the proportion of women whose symptoms were
improved based on clinical measures such as pad tests,
urinary diaries or quality of life scores.
In line with the recommendations of the International
Continence Society, outcomes were considered the under
the following five categories [29]:
A. Women's observations (subjective measures)
• Perception of cure and improvement
B. Quantification of symptoms (objective measures)
• Pad changes over 24 hours (self-reported)
• Incontinent episodes over 24 hours (self-completed
bladder chart)
• Pad tests of quantified leakage (mean volume or weight
of urine loss)
C. Clinician's observations
• Objective assessment of pelvic floor muscle strength
D. Quality of life
• General health status measures (physical, psychological,
other)
• Condition-specific health measures (specific instru-
ments designed to assess incontinence)
E. Socioeconomic measures
• Health economic measures
This review also included other information about pro-
gression to surgical intervention and adverse events. All
outcome measures were documented and categorized
under the headings described above.
Search strategy
To identify all relevant studies for the review, the search
strategy comprised searches of the following:
Bibliographic Databases:MEDLINE, CINAHL, AMED,
Current Contents, The Cochrane Library, Cochrane Data-
base of Systematic Reviews (CDSR), The Cochrane Con-
trolled Trials Registers (CCTR), SPORTdiscus, CatchWord,
AUSTHealth, Academic search elite, Science Direct,
PubMed, Ageline, PEDro, OVID
Internet source: http://www.yahoo.com, http://
www.google.com
Reference lists of systematic reviews, meta-analyses,
reviews and the studies identified by the search strategy
above were pearled for additional relevant source mate-
rial. Their inclusion was validated by checking their key
words against the search terms. Hand searching for pub-
lished and unpublished data was not performed because
a systematic and thus reproducible approach could not be
guaranteed.
All relevant studies with an English language abstract were
located for assessment against the inclusion criteria. Date
of the last search was 20 May 2005. Individual strategies
were developed for each source searched to accommodate
search engine idiosyncrasies. The core terms and search
strategies used for each literature source are listed in addi-
tional file 1.
Eligibility criteria
Study selection
Relevant articles were identified from the hits produced
from each library database, internet source or reference
lists by applying the eligibility criteria. The relevant eligi-
ble studies were documented in a Microsoft Excel (2000)
database [see additional file 2].
The full text version of all relevant peer-reviewed studies
was obtained where possible, and abstracts were only
included as a proxy for the complete text if sufficient data
was available in the abstract to assess and fulfil all the eli-
gibility criteria, to critically appraise and to provide point
measures on at least one measure of outcome. Inclusion
of studies into this review was reached by consensus
between the two reviewers.BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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Assessment of methodological quality
Level of evidence
The level of evidence of each retrieved study was assessed
using the Australian National Health & Medical Research
Council [24] levels of evidence [see additional file 3] in
order to describe potential for bias.
Methodological quality
To evaluate the methodological quality of the included
studies, each study was critically appraised by two inde-
pendent reviewers using a purpose-built critical review
instrument [see additional files 4 &5]. The purpose-built
instrument was a modification of the tool developed by
the McMaster University Occupational Therapy Evidence-
Based Practice Research Group [30]. This appraisal tool is
a critical review form for quantitative studies considering
eight main points: study purpose, literature, study design,
sample, outcomes, intervention, results, conclusions and
clinical implications. Although this tool was designed for
all types of quantitative studies, other authors have rec-
ommended a separate tool for each of the two main types
of design: experimental and observational studies [31].
We developed our tools drawing on information from the
Agency for Healthcare Research and Quality report 'Sys-
tems to Rate the Strength of Scientific Evidence' [31] and
from the Centre for Reviews and Dissemination, Univer-
sity of York [21]. The modified tool developed for this
review provides a maximum quality rating score of 23 for
RCTs and a maximum score of 19 for non-RCTs. It was
pilot-tested and modified a number of times before
implementation to ensure content and face validity, and
agreement on its application by the reviewers involved in
this review. The final version of the purpose-built instru-
ment was then applied by two reviewers working inde-
pendently. They then compared critical appraisal scores
and resolved disagreements in scoring by discussion.
Details of the quality assessment are provided [see addi-
tional files 4 &5] with studies ranked according to their
quality assessment score to provide readers with an over-
view of their methodological quality. All the studies were
then considered for the strength of their evidence, based
on the quality score and with particular consideration of
the factors which were concerned with control of bias.
Studies with a high quality score were considered to show
evidence of good control of bias (eg attention to random
allocation processes, baseline similarity of groups, reliable
outcome measures) as well as other factors concerning
quality reporting, such as consideration of ethical proc-
esses and relevance of the literature review. Studies with a
high quality score are identified and highlighted by the
reviewers in the text for their contribution to evidence
about treatment outcomes.
Data extraction
Relevant data was extracted from each study in a separate
extraction sheet, providing a profile of each study using
the following headings:
• Information about service delivery (health professional
and setting/institution)
• Demographic information about the subjects in the
study
• Study methods
• Descriptions of the intervention(s)
• Description of the outcome measure(s)
• Key results from data analysis – short term and at 12
months
Similar to the process of critical appraisal, both reviewers
extracted information independently and where there was
disagreement, consensus was reached by discussion or in
consultation with a third party
Data synthesis
Because our review included studies of evidence levels II,
III and IV (NHMRC 1999), and because study measures
were not homogenous, it was not possible to analyse the
data by meta-analysis. Thus findings are presented as nar-
rative summaries. In studies with a 'no treatment' or 'usual
treatment' control group, analysis of between-group
effects were reported in this analysis. In studies without a
control group, within-group changes were used to calcu-
late treatment effects. All relevant outcomes ie those fit-
ting the inclusion criteria, were reported, including
statistically significant and non-significant findings.
Results
Methodological quality and description of studies
The search identified 7760 potentially relevant research
reports in the period 1995–2005, of which 24 studies ful-
filled the inclusion criteria and hence were considered in
this review. Twenty one included studies were English
peer-reviewed research reports, three were peer-reviewed
conference abstracts with no published full-text report
and one was a peer-reviewed foreign language paper with
an English language abstract. This English abstract was
used for data extraction. There was 100% agreement
between the reviewers in terms of study inclusion. Sum-
maries of the studies included in the review are provided
in Tables 1 and 2. Studies are presented in order of their
quality assessment score with information about the level
of evidence, interventions investigated and information
to determine the generalisability of the study findings.BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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Arms of studies were excluded where there was no descrip-
tion of a specific PFMT protocol. Thus the following
arm(s) were excluded: Cammu & van Nylen (1997) [32]
(VW only), Sung et al (2000) [33] (ES/BF) and Bo et al
(1999) [34](ES, VW).
• Hierarchy of evidence
There was initially 91% agreement (Cohen's Kappa: 0.8)
between the reviewers regarding the level of evidence
assigned to each study (NHMRC, 1999). A Kappa score of
more than 80% is considered to represent 'excellent'
agreement and between 60–80% 'substantial' agreement
[35]. Complete agreement was reached after discussion.
Seventeen of the 24 studies identified were RCTs
[32,34,36-50]. Seven were non-RCTs, of which three were
level III-2 studies ie cohort or interrupted time series with
a control group [33,51,52] and four were level IV studies
ie case-series (before-after investigations) without a con-
trol group [53-56].
• Methodological quality of included studies
There was initially 83% agreement (Cohen's Kappa: 0.65)
between the reviewers regarding the methodological qual-
ity of the included studies. After consultation, 100%
agreement was reached. The methodological quality of
the studies was variable with the highest scoring 100%
(23/23) [34] and the lowest (26%) 5/19 [55]. There was
no correlation between a more recent date of publication
and quality score (Pearson's correlation – 0.03, p > 0.05).
A summary of the quality assessment of the 17 level II
studies [see additional file 4] and the seven level III & IV
studies [see additional file 5] is provided. The methodo-
logical quality of the RCTs varied from 23/23 (100%) [34]
to 9/23 (39%) [36]. The methodological quality of the
level III and IV studies was also variable with scores from
14/19 (74%) [51] to 5/19 (26%) [55]. Studies with a
lower quality score contained a number of sources of bias
which should be considered when interpreting the results.
However, the four studies in abstract form had limited
Table 1: Summary of all studies with interventions, level of evidence, quality rating score and age
Studies Intervention Hierarchy of
Evidence a
Quality Rating Score (%) Mean age (SD)b
Bo (1999) PFMT v BF v ES v control II 23/23 (100) 49.6 (10)
Morkved (2002) PFMT v PFMT+BF II 22/23 (96) 47.8 (8.2)
Dumoulin (2004) PFMT+ES+BF v PFMT+ES+BF+Ab Ex v control II 21/23 (91) 36.2 (median)
(IQ range 23–39)
Bo (2000) PFMT II 21/23 (91) 49.6 (10)
Berghmans (1996) PFMT v PFMT+BF II 20/23 (87) 48 (range 18–70)
Knight (1998) PFMT+BF v PFMT+BF+ES('home') v 
PFMT+BF+ES('clinic')
II 17/23 (74) NR (range 24–68)
Miller (1998b) PFMT (motor learning) II 17/23 (74) 68.4 (range 60–84)
Parkkinen (2004) PFMT+ES+BF+VW v PFMT+VW III-2 14/19 (74) 46.8 (range 32–65)
Wong (2001) PFMT+BF v PFMT+BF+Ab BF II 16/23 (70) 46 (range 30–62)
Dumoulin (1995) PFMT+ES+BF IV 13/19 (68) 32 (9.5)
Johnson (2001) PFMT (SVC) v PFMT (NMVC) II 15/23 (65) 50 (35–65)
Hay-Smith (2002) A PFMT (motor learning/strength) v PFMT (motor 
learning)
II 15/23 (65) 48.8 (13.2 SD)
Arvonen (2001) PFMT v PFMT+VW II 15/23 (65) 48 (range 28–65)
Cammu & van Nylen (1998) PFMT+BF v VW II 15/23 (65) 55.9 (9.5)
Turkan (2005) PFMT+ES III-2 11/19 (58) 47.6 (8)
Pieber (1995) PFMT+BF v PFMT+BF+VW II 13/23 (57) 43 (+/- 6)
Chen (1999) PFMT+ES IV 11/19 (58) NS (range 20 to 
>50)
Glavind (1996) PFMT v PFMT+BF II 13/23 (57) 45 (median)(range 
40–48)
Pages (2001) PFMT v BF II 13/23 (57) 51.1 (range 27–80)
Bidmead (2002) A PFMT v PFMT+ES v PFMT+sham ES v control II 10/23 (43) NR
Sung (2000) PFMT III-2 8/19 (42) range 18 – >60
Aksac (2003) PFMT v PFMT+BF v control II 9/23 (39) 52.9 (7.2)
Balmforth (2004) A PFMT+BF IV 6/19 (32) 49.5 (10.6)
Finkenhagen (1998) A PFMT IV 5/19 (26) 49 (range 25–67)
A = available in English only as abstract; a = According to Australian National Health and Medical Research Council Hierarchy of Evidence (1998); b 
= Mean age (SD) unless otherwise stated; PFMT = pelvic floor muscle training; ES = electrical stimulation; BF = biofeedback; VW = vaginal weights; 
PT = physiotherapist; UDS = urodynamics studies; NR = not reported, SVC = submaximal voluntary contraction, NMVC = near-maximal voluntary 
contractionBMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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information for quality assessment contributing to their
lower quality scores.
Types of participants
Women were included with a urodynamic diagnosis of
SUI, a clinical diagnosis based on signs and/or symptoms,
or a combination of the above [1]. There was considerable
variation in the hormonal status and age (18–84 years) of
subjects in this review. Two studies [41,56] specifically
recruited younger, pre-menopausal women with SUI per-
sisting at least 3 months after the last childbirth. These
authors stated that this time was chosen to allow the hor-
monal changes from pregnancy and parturition to have
resolved. Another study [49] also specifically recruited
pre-menopausal women. By contrast, Miller et al (1998)
recruited older women with a mean age of 68 (range 60–
84) and Aksac et al (2003) reported on women with a
mean age of 53 (SD 7.2) years who were all using oral hor-
mone replacement therapy. All other studies investigated
various combinations of PFMT and adjunctive therapies
in women with a mean age 46–56 (range of 18–80). Some
of these studies stated that their populations included
women who were both pre- and post-menopausal
[33,34,38,43,47,54]. There was therefore considerable
heterogeneity in the studies reviewed in terms of possible
confounding due to age and hormonal status.
Identification and/or control of potential confounders
The following confounding variables were controlled by
stratification in a number of studies: severity of symptoms
[34,38,41,47], referral source [34,38,41,47] and parity
[34].
The initial severity of incontinence was not always
reported and methods used to describe severity varied
considerably so that any comparisons should be made
with caution (Table 3). Two studies included women with
a past history of surgery for incontinence [45,51]. In
twelve studies, it was stated that women were excluded if
they had prior surgery for incontinence [34,38,41-
43,46,47,49,50,52-54] and it was not reported in nine
other studies [32,33,36,37,39,40,44,48,56].
Recruitment methods varied across the included publica-
tions, which potentially influenced subjects' responses to
intervention. In three studies, the participants were volun-
teers who responded to newspaper advertisements [47] or
from outpatient hospital populations [41,56]. In three
Table 2: Summary of studies with factors pertaining to external validity
Studies Diagnosis Intervention by Setting Excluded if prior 
surgery
Volunteers (V) or 
Referred (R)
Bo (1999) S, Pad T, UDS PT Multicentre yes V+R
Morkved (2002) S, Pad T, UDS PT NR yes V
Dumoulin (2004) S, Pad T, UDS PT NR yes V
Bo (2000) S, Pad T, UDS PT NR yes NR
Berghmans (1996) S, CST, Pad T, UDS PT PT clinic yes R
Knight (1998) UDS PT Tertiary Clinic no NR
Miller (1998) S, CST NR NR yes NR
Parkkinen (2004) S, Pad T, UDS PT Hospital PT clinic no NR
Wong (2001) S, UDS PT Hospital PT clinic yes R
Dumoulin (1995) S, Pad T, UDS PT NR NR V
Johnson (2001) S, UDS NR NR yes V+R
Hay-Smith (2002) S, CST, Pad T PT NR yes V+R
Arvonen (2001) S PT OP PT clinic no R
Cammu & van Nylen (1998) S, UDS PT NR no NR
Turkan (2005) S, Pad T, UDS PT University PT clinic yes R
Pieber (1995) UDS PT Urodynamic unit yes R
Chen (1999) S, CST, Pad T, UDS NR NR yes R
Glavind (1996) S, Pad T, UDS NR NR yes NR
Pages (2001) S, UDS PT OP hospital clinic no R
Bidmead (2002) UDS PT NR NR NR
Sung (2000) S PT NR NR R
Aksac (2003) UDS Therapist NR NR NR
Balmforth (2004) S, UDS PT NR yes R
Finkenhagen (1998) NR PT PT clinic (primary care) NR NR
S = symptoms, Pad T = pad test, CST = cough stress test, UDS = urodynamic studies, NR = not reported, PT = physiotherapist, OP = outpatientBMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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studies, participants were both volunteers and referred
[34,43,44]. In ten other studies, they were referred by a
medical practitioner or recruited from a tertiary institu-
tion clinic population [33,37,38,45,48-50,52-54] and in
the remaining studies the source was not reported
[32,36,39,40,42,46,51,55].
Types of interventions
The studies were divided into intervention categories and
results summarised according to the different interven-
tions reported: 14 studies reported on PFMT alone (Table
4), 11 studies on PFMT with BF (Table 5), three studies on
PFMT and ES (Table 6), two studies on PFMT and VW
(Table 7), three studies on PFMT with BF and ES (Table 8),
one study on PFMT, BF and VW, (Table 9), and one study
on PFMT combined with ES, BF and VW (Table 10).
Details of the protocols for the interventions for all studies
are detailed in Table 11.
• Pelvic floor muscle training
Studies were described by the broad types of PFMT which
were employed, ie specific strength training (inducing
muscle hypertrophy) or skill training (improving motor
learning), and their exercise dosage (frequency, intensity,
duration of the training programs and compliance) [10].
The effect of specifically activating or de-activating the
abdominal wall during PFMT was investigated. While
reducing abdominal muscle activity has been advocated
to isolate the PFM and minimise intra-abdominal pres-
sure (Laycock, 1994), more recently a synergistic activity
of the deep abdominal muscles (transversus abdominis
and lower fibres of obliquus internus) and PFM has been
described [57-59]. Training of the deep abdominal mus-
cles as a treatment for incontinence has been advocated
[60] but more recently disputed [10].
• Biofeedback
Many different applications of biofeedback were
described. Vaginal applications of EMG
[32,36,38,41,42,50,51], pressure devices
[44,45,47,48,56] or perineal ultrasound [49,53] were
described. Three studies applied surface EMG BF on the
surface of the abdominal wall as well to indicate abdomi-
nal muscle activity [32,42,50]. The EMG electrodes were
placed over the rectus abdominis in one study [50] but the
placement was not specified in the other two studies. Vag-
inal BF was used as a home treatment in three studies
[44,45,47], as home and clinic treatment in one study
[45] and in the others it was used only at clinic visits. One
study [42] used additional rectal pressure BF to monitor
intra-abdominal pressure.
Two studies used trans-perineal ultrasound to teach a cor-
rect elevating contraction at the first clinic visit [49,53]
and in one study ultrasound was repeated for PFMT on
two further occasions [49]. Another study [36] did not
Table 3: Baseline severity of symptoms: incontinent episodes (IE) and urine loss (g) (pad test)
Study IE/day IE/week Urine loss (g) (pad test)
Aksac (2003) 20 (1 hour)
Arvonen (2001) 25 (SPT, st.b.vl)
Balmforth (2004) 12.2 (SPT, st.b.vl)
Berghmans (1996) 2–3 28 (48 hr pad test)
Bidmead (2002) 10 (SPT)
Bo (1999) 2.0 per 3 days 38.6 (SPT, st.b.vl.); 14.5 (24 hr pad test)
Bo (2000) 45 (SPT, st.b.vl)
Cammu & van Nylen (1998) 14.4 NR
Chen (1999) 5.5 20 (1 hour)
Dumoulin (1995) 74.4 (SD 84.3) (SPT, st.b.vl)
Dumoulin (2004) PF group: 12.5 g: PF+ abs group: 20 g (SPT, st.b.vl)
Finkenhagen (1998) NR
Glavind (1996) 10.9 (SPT, st.b.vl)
Hay-Smith (2002) 1.8 3.9 ml (paper towel test)
Johnson (2001) 3.6 (range: 1.86–13) 12.9 (range: 1.76–111.42) (10 hour pad test)
Knight (1998) 14.6 (SPT, st.b.vl)
Miller (1998) Paper towel test
Morkved (2002) 27.5 (SPT, st.b.vl), 42.2 (48 hr pad test)
Pages (2001) NR
Parkkinen (2004) (SPT, st.b.vl)
Pieber (1995) NR
Sung (2000) NR
Turkan (2005) (1) 8.6 (2) 29.1 (3) 236.4) (1 hour pad test)
Wong (2001) 6.3 10.8 (SPT, standardised fluid intake)
SPT = stress pad test; st.b.vl = standardised bladder volumeBMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
Page 9 of 28
(page number not for citation purposes)
Table 4: Outcomes of studies of PFMT with percentage cure, cure/improvement and positive and statistically significant outcomes
PFMT studies Treatment time N (subjects) N (% lost to
follow-up)
% cure % cure/improved N (%) positive & 
statistically significant 
outcomes
Bo (1999) 6 months 29 4 (14) 44 (1), 56 (4) 48 (4) 8/9 (89)
Morkved (2002) 6 months 50 4 (17) 46 (1), 30 (4) 57 (2) 93 (4) 6 (100)
Bo (2000) 6 months 24 4 (8) 6–44 (5) NR 1 (100)
Berghmans (1996) 4 weeks 20 0 (0) 15 (2) 85 (2) 1 (100)
Miller (1998b) 1 week 27 0 (0) 23 (3) NR 2 (100)
Hay-Smith (2002)a 20 weeks 64 2 (3) 7 (4) 47 (4) NR
Hay-Smith (2002)b 20 weeks 64 3 (5) 2 (4) 41 (4) NR
Arvonen (2001) 4 months 20 1 (5) 26 (1) 58 (4) 3 (100)
Glavind (1996) NR (2–3 sessions) 20 5 (25) 20 (1) NR NR
Pages (2001) 3 months 27 0 (0) 69 (4) 100 (4) 3 (100)
Bidmead (2002) 14 weeks 40 NR NR NR 3 (100)
Sung (2000) 6 weeks 30 NR NR NR 3 (100)
Aksac (2003) 8 weeks 20 NR 75 (3) 100 (3) 10 (100)
Finkenhagen (1998) 6 months 38 2 (5) 35 (4) 71 (4) NR
Hay-Smith a = motor learning protocol, Hay-Smith b = strength and motor learning protocol NR = not reported; (1) = pad test with standardised 
bladder volume; (2) = 48 hour pad test; (3) = other types of pad test; (4) = self-rated assessment of incontinence; (5) = self-reported quality of life/
sexual function domains
Table 5: Outcomes of studies of PFMT and BF with percentage cure, cure/improvement and positive and statistically significant 
outcomes
PFMT+BF studies Treatment time N (subjects) N (% lost to 
follow-up)
% cure % cure/improved N (%) positive & 
statistically significant 
outcomes
Morkved (2002) 6 months 53 5 (9) 58 (1); 65 (2) 40 (3) 97 (3) 6 (100)
Berghmans (1996) 4 weeks 20 0 (0) 25 (2) 95 (2) 1 (100)
Knight (1998) 6 months 21 3 (14) NR 72 (1) 56 (3) 2 (100)
Wong (2001) a 4 weeks 19 0 (0) NR NR 3/5 (60)
Wong (2001)b 4 weeks 19 0 (0) NR NR 4/5 (80)
Johnson (2001) a 6 weeks 16 0 (0) 25 (3) NR 4 (100)
Johnson (2001) b 6 weeks 16 0 (0) 38 (3) NR 2/4 (80)
Cammu & van Nylen (1998) 12 weeks 30 0 (0) 53 (3) NR NR
Pieber (1995) 3 months 25 11 (44) 22 (3) 86(4) NR
Glavind (1996) 4 weeks 20 1 (5) 58 (4) NR NR
Pages (2001) 1 month 24 11 (46) 62 (3) 100 (3) 1 (100)
Aksac (2003) 8 weeks 20 NR 80 (4) 100 (4) 8 (100)
Balmforth (2004) 14 weeks 97 NR NR NR 5 (100)
NR = not reported; (1) = stress pad test with standardized bladder volume; (2) = 48 hour pad test; (3) = self-report; (4) = 1 hour pad test; Wong a 
= vaginal BF; Wong b = vaginal BF plus rectus abdominis BF; Johnson a = Training with Submaximal Voluntary Contractions; Johnson b = Training with 
Near Maximal Voluntary Contractions
provide clear details whether pressure BF was used for
teaching only or training as well.
• Electrical stimulation
Electrical stimulation was used in seven studies in differ-
ent combinations of therapy. [33,39,45,51,52,54,56].
Three studies investigated PF/ES, four studies a combina-
tion of PFMT/BF/ES, and one study a combination of
PFMT/ES/BF/VW. The application and protocols varied
considerably. Two studies used interferential currents
with externally applied suction cups with clinic treatment
[52,56]. The others used vaginal application either with
home stimulation [39,45] or at clinic visits [45,54].
• Vaginal weights
Different types of vaginal weights were used varying from
20 g to 100 g. Protocols required women to perform activ-
ities of daily living while retaining the weight in the
vagina [37,49,51], while one [37] required women to per-
form 'gymnastics' in addition to routine daily activities
but no details of this activity or of subjects' compliance
were provided. In all three studies women additionally
performed a PFMT program.BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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Types of outcomes
A summary of the outcome measures used in terms of the
ICS recommendations is presented in Table 12. Outcomes
were reported under all categories except socioeconomic
variables which were not reported in any study. However,
in each category, different instruments were used or mod-
ifications of the same instrument. For example, in cate-
gory 2 (quantification of symptoms by objective
measures) the results of 19 pad tests were reported. Two
were performed for 48 hours, two for 24 hours, one for 10
hours. In addition, eight different provocative pad tests
with standardised bladder filling were performed
Table 9: Outcomes of studies of PFMT, BF and VW with percentage cure, cure/improvement and positive and statistically significant 
outcomes
PFMT+BF+VW 
studies
Treatment time N (subjects) N (% lost to 
follow-up)
% cure % cure/improved N (%) positive & statistically 
significant outcomes
Pieber (1995) 3 months 21 8 (38) 38.5 (1) 84.5 (1) NR
(1) = subjective rate of cure
Table 7: Outcomes of studies of PFMT and VW with percentage cure, cure/improvement and positive and statistically significant 
outcomes
PFMT+VW studies Treatment time N (subjects) N (% lost to 
follow-up)
% cure % cure/improved N (%) positive & statistically 
significant outcomes
Parkkinen (2004) 12 months 19 3 (16) NR a NR a 3 (100)
Arvonen (2001) 4 months 20 2 (10) 50 (1); 22 (2) 61 (2) 2 (100)
(1) = objective cure based on pad test with standardised bladder volume, (2) = subjective rating of cure; a = not reported at 12 months
Table 6: Outcomes of studies of PFMT and ES with percentage cure, cure/improvement and positive and statistically significant 
outcomes
PFMT+ES studies Treatment time N (subjects) N (% lost to 
follow-up)
% cure % cure/improved N (%) positive & 
statistically significant 
outcomes
Turkan (2005) 5 weeks 17 0 (0) Total: 38 (1) a: 88; b: 1; c: 0 NR 4 (100)
Chen (1999) 3 months 
intensive, 21 m 
home training
72 0 (0) 7 (2) 61 (2) NR
Bidmead (2004) 14 weeks 97 NR NR NR 3 (100)
NR = not reported; (1) = self-rated assessment of incontinence; (2) = other type of pad test; Turkan: % subjects cured in groups a,b,c stratified by 
baseline severity of incontinence based on 1 hour pad test a: mild incontinence: 0–2 g; b: moderate incontinence: >2–10 g; c: severe: >10 g
Table 8: Outcomes of studies of PFMT, ES and BF with percentage cure, cure/improvement and positive and statistically significant 
outcomes
PFMT+ES+BF studies Treatment time N (subjects) N (% lost to 
follow-up)
% cure % cure/improved N (%) positive & statistically 
significant outcomes
Dumoulin (2004) a 8 weeks 21 1 (5) 70 (1) 90 (1) 8/9 (89)
Dumoulin (2004) b 8 weeks 23 0 (0) 73 (1) 90 (1) 8/9 (89)
Knight (1998) a 6 months 25 6 (24) NR 53 (1)
47 (2)
2 (100)
Knight (1998) b 6 months 24 4 (17) NR 80 (1)
80 (2)
2 (100)
Dumoulin (1995) 3 weeks 10 2 (20) 62.5 (1) 100 (1) 3 (100)
(1) = Pad test with standardised bladder volumes, (2) = subjective report; Dumoulin a: training protocol with PFMT, ES, BF; Dumoulin b: training 
protocol with PFMT, ES, BF and specific deep abdominal muscle training; Knight a: training protocol with PFMT, BF, ES ('home' low intensity, 10 Hz); 
Knight b: training protocol with PFMT, BF, ES ('clinic' high intensity, 35 Hz)BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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[34,40,41,45,47,51,53,56] and another four 'standard-
ised' pad tests were reported without details of either blad-
der filling or provocation [36,42,52,54]. One test using
paper towel instead of a pad to quantify urine loss under
coughing provocation was reported [46]. This variability
precludes precise comparison of outcomes.
A summary of all the positive and statistically significant
(p < 0.05) and the non-significant measures of effect for
each category of study (PFMT, PFMT/BF etc) is presented
in Figure 1. Each measure is displayed for within-group or,
if there was a no-treatment control group, also for
between group differences.
Psychometric properties
None of the level III & IV studies and nine of the 16 level
II studies included statements about the reliability and
validity of the outcome measures used [see additional
files 4 &5]. The use of outcome measures which are valid,
reliable and sensitive to change is vital when considering
the effects of treatment in order to detect valid changes
which are greater than measurement error [61]. Caution
must be exercised when considering the results of studies
where valid and reliable outcome measures have not been
used.
Outcomes in terms of cure/improvement
The definitions used for 'cure' and 'improvement' varied
widely and are listed in Table 13. Five studies
[33,39,50,51,53] did not report their outcomes in terms
of the numbers (percentages) of subjects who were cured/
improved at all. All estimates of 'cured' and 'improved' are
expressed as the percentage of subjects who completed
treatment compared with the number who started treat-
ment. The number (percent) of withdrawals is presented
to permit estimates of bias.
Other outcomes
Four studies reported on the numbers of women who had
surgery either during the study or after completion of
treatment [32,47,49,51]. Ten studies reported on the
occurrence of any adverse events as a result of treatment
[34,41,42,46-49,51,54,55].
1. What is the evidence for PFMT, either alone or in combination with 
adjunctive therapies, when considering all treatment protocols, for 
the treatment for SUI in women, in the short and medium terms (up 
to 12 months after treatment)?
1.1 PFMT alone
Twelve 12 RCTs with 13 treatment arms, one level III-2
and one level IV studies investigating PFMT protocols
were identified (Table 4). Cure rates ranged from 2% [43]
to 75% [36,43] and rates of cure/improved ranged from
41% [43] to 100% [48]. However, when considering the
evidence from the two studies with >90% quality scores
[34,47], reported cure rates were 44% to 57% and 'cure/
improvement' rates from 48% to 93%, depending on the
definition of cure/improvement. These two studies dem-
onstrated treatment effects based on 13 different measures
of outcome. Both reported pad test and self-report of
symptoms giving conflicting findings. Bo (1999) reported
a higher cure rate with subjective assessment (56%) while
Morkved (2002) reported a higher cure rate with objective
assessments (46% with a short provocative pad test and
57% with 48 hour pad test). Direct comparisons between
study outcomes are to be considered with caution due to
the range of definitions of cure and improvement
reported.
No adverse events were reported as a result of PFMT
[34,42,46,47,55]. Two studies reported the number of
subjects having surgical intervention either during (4.3%)
[47] or at the end of the study (17%) [32].
Considering all study designs, 28/29 (97%) different
measures of incontinence reported a positive and statisti-
cally significant change. Thus in considering the strength
of evidence for PFMT, there is strong evidence from a
number of high quality level II studies, with consistently
positive and significant findings, based on multiple meas-
ures of outcome that PFMT is effective for women with
SUI.
1.2 PFMT with BF
Ten RCTs with 12 study arms (quality scores: 96% [47] to
39% [36]) and one level IV study were identified reporting
the outcomes of PFMT combined with BF training (Table
Table 10: Outcomes of studies of PFMT, BF, ES and VW with percentage cure, cure/improvement and positive and statistically 
significant outcomes
PFMT+BF+ES+VW 
studies
Treatment time N (subjects) N (% lost to 
follow-up)
% cure % cure/improved N (%) positive & statistically 
significant outcomes
Parkkinen (2004) 12 months 19 2 (11) NR a NR a 3 (100)
NR a = not reported at 12 monthsB
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Table 11: Summary of interventions
Studies/arms of studies Control group 
protocol
PFM action taught
1 = digital vaginal
2 = other
PFMT protocol (s/s) = 
Contraction time in 
seconds/relaxation time in 
seconds
Intensity of 
contract-ions or 
type of PFM T
Adjunctive 
therapy
Adjunctive therapy 
protocol
Duration of
intervention
N of treatments 
(individual unless 
other-wise 
stated)
Aksac 2003 PFMT 1 5s/10s, 10 reps, 3 sets/
day. After 2 weeks, 10s/
20s relax. Weekly 
individual sessions.
NR. Relaxation of 
abdominals, 
gluteals
8 weeks 8
Aksac 2003 PFMT+BF 2 10s/20s, 40 reps, 3 sets/
week. Weekly individual 
sessions.
NR EMG vaginal BF 
to learn action 
only
No home training with 
BF.
8 weeks 8
Aksac 2003 Control 
group
No PFMT NA
Arvonon 2001 PFMT NA 1 5s/5s, 10 reps (max), 
seated/standing, 2 sets/
day. 3s/3s, 15 reps, 
(submax) 1 set/day 2 min. 
sustained (submax) 1 rep, 
1 set/day. 3 clinic visits
Maximal, 
submaximal
4 months 3
Arvonon 2001 
PFMT+VW
NA 1 a/a VW VW (50 g, 65 g, 80, 
100 g) 20s/20s, (max) 
10 reps, standing, 2 
sets/day. 15 mins. VW 
with daily activities, 
gymnastics.
4 months 3
Balmforth 2004 PFMT+BF NA 2 Perineal 
ultrasound
Intensive + individualised 
PFMT + 'behavioural 
modification' program 
Home program: NR
NR Perineal 
ultrasound to 
teach correct 
contraction. 
Pre-treatment 
only.
14 weeks NR
Berghmans 1996 PFMT NA 1 3–30s contractions, 10–30 
reps, supine/standing/all 
fours. PFE with coughing, 
stairs, lifting, jumping. 
Home: 3x/day.
NR 4 weeks 12
Berghmans 1996 
PFMT+BF
NA 1 a/a NR EMG vaginal BF 
Clinic only.
Individual program for 
12 sessions.
4 weeks 12B
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Bidmead 2002 PFMT NR 'Conventional 'PFE by 
experienced research 
physiotherapist. Home: 
details NR
NR 14 weeks NR
Bidmead 2002 PFMT+ES NR ES (no details 
reported)
Same PFE program 
with home ES
14 weeks NR
Bidmead 2002 Control 
group
No treatment
Bo 1999 PFMT 1 6–8s/6 s, 8–12 reps, 3–4 
fast contractions at end of 
'hold', 3 sets/day. Weekly 
group sessions with ex in 
different positions and for 
abdominals, back, thighs. 
Monthly PFM assessment.
High intensity 6 months 24 group 6 
individual
Bo 1999 Control group No contact. 
Offered 
Continence Guard
Bo 2000 PFMT NR As for Bo 1999 6 months 24 group 6 
individual
Bo 2000 Control group No contact 
Offered use of 
Continence Guard
Cammu & van Nylen 
1998 PFMT+BF
NA 1 'Brief' + 10s contractions, 
10 reps, as many sets as 
possible 'within patients 
capacity'. Home: 
Increasing number of sets
Maximal BF vag EMG + 
'abdominal' 
EMG to reduce 
Valsalva efforts
Individual: Weekly, 30 
min BF session
12 weeks 6
Chen 1999 PFMT+ES NA 1 No details. 15 mins 2 sets/
day, 3 months Then 15 
mins/day, 1 set/day, 21 
months
ES intravaginal, 
home 
stimulator
Increasing tx times: 
20,40, 60 min, 2/week, 
3 months. Biphasic 
square wave, 25 Hz.
3 months 
(ES) 24 
months 
(PFE)
24 + 6
Dumoulin 2004 
PFMT+ES+BF
NR Standardised reeducation 
program. Home: 5 days/
week: no details. Weekly 
individual sessions
Strength & motor 
learning
1. ES vag
2. BF vag EMG. 
Clinic only
1. ES:15 mins 6s on/
18s off, weeks 1–4, 8s 
on/24s off, weeks 5–8. 
50 Hz, 250 msec.
2. BF 25 min
8 weeks 8
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Dumoulin 2004 
PFMT+ES+BF+ abdominal 
exercises
NR a/a Additional weekly 30 
min session with deep 
abdominal muscle training
a/a a/a a/a 8 weeks 8 + 8 group 
sessions for 
abdominal 
muscle training
Dumoulin 2004 Control 
group
weekly massage 
with PT
8 weeks
Dumoulin 1995 
PFMT+BF+ES
NA 1 5s/10 s, 10 reps, 2 sets 
Home: 4 sets/day 
Individual session with ES/
BF 3x/week.
Maximal 1. ES 
Interferential 
current 4 
suction 
electrodes
2. BF vag 
pressure Clinic 
only
1. ES 15 mins 10–50 
Hz, 15 mins 50 Hz.
2. BF 15 mins
3 weeks 9
Finkenhagen 1998 PFMT NA 1 6–8 s/6 s, 8–12 reps, 3–4 
fast contractions at end of 
'hold'. Home: 8–12 reps, 3 
sets/day. Weekly exercise 
class (protocol as for Bo 
1999)
Strength 6 months 1 individual + 24 
group training
Glavind 1996 PFMT NA 1 'standard procedure' – no 
details given. Individual 
sessions 2–3 times
NR 4 weeks 2–3
Glavind 1996 PFMT+BF NA NR 5–10s contractions, 10 
reps in supine, sitting, 
standing, Individual 
instruction
NR BF vag EMG + 
rectal pressure 
BF to avoid IAP 
rise
4 weekly sessions. 
Clinic only.
4 weeks 6–7
Hay-Smith 2004 PFMT a NA NR PFMT :motor relearning 
alone Home: no details
Motor learning 20 weeks 4 + 3 phone calls
Hay-Smith 2004 PFMT b NA NR PFMT: strengthening plus 
motor relearning. Home: 
no details
Strength & motor 
learning
20 weeks 4 + 3 phone calls
Johnson 2001 PFMT 
(SVC) +BF
NA 2. Vaginal perineo 
meter
10 s/10s, 15 minutes, 
submaximal (60% of 
MVC). 3 sets/day
Submaximal 
VoluntayContracti
ons
BF vag 
pressure. 
Rectus EMG BF 
for first instruct 
ion
BF home training 6 weeks 2
Johnson 2001 PFMT 
(NMVC) +BF
NA 2. Vaginal perineo 
meter
10s/10s, 10 minutes, near-
maximal (90% of MVC). 3 
sets/day
Near-maximal 
Voluntary 
Contract ions
BF vaginal 
pressure Home 
trainer
6 weeks 2
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Knight 1998 PFMT+BF NA 1 Up to 10s/4s 
(individualised), fast (up to 
10), up to 10 reps, 6 sets a 
day. 6–18 months:1 set/
day
Maximal BF vaginal 
pressure. 
Home trainer + 
clinic.
Home trainer: 1 set 
PFX per day. Clinic: 
weekly for 1 month, 
then bi-weekly. 6–18 
months: BF 1/week
6 months 14
Knight 1998 
PFMT+BF+ES (home)
NA 1 a/a Maximal As for 
PFMT+BF plus 
ES (home)
Vaginal, overnight, 10 
Hz, 200 ms. 5 on/5 off. 
Low intensity. 6–18 
months: BF 1/week
6 months 14
Knight 1998 
PFMT+BF+ES (clinic)
NA 1 a/a Maximal As for 
PFMT+BF plus 
ES (clinic)
Vaginal, 16 × 30 min., 
35 Hz, 250 ms. 5 on/5 
off. High intensity, 
contraction with 
stimulator. 6–18 
months: BF 1/week
6 months 14 PFMT+BF 16 
ES
Miller 1998 PFMT NA 1 Taught to contract and 
cough. Home practice.
Motor learning 1 week 2
Morkved 2002 PFMT NA 1 6–8s/6 s, 8–12 reps (high 
intensity). 3–4 fast 
contractions at end of 
'hold. Home: 3 sets/day. 
Individual sessions
High intensity 6 months 16
Morkved 2002 PFMT+BF NA 1 a/a with home BF. 
Individual sessions
High intensity BF vaginal 
pressure home 
trainer
6–8s/6 s, 8–12 reps 
(high intensity). 3–4 
fast contractions at 
end of 'hold', 3 sets 
daily
6 months 16
Pages 2001 PFMT NA 1 Group 5/week. Home: 
100 reps/day during daily 
activities. Supine 10 mins, 
2 sets/day. Group: 
different positions
'Isolated' 
contractions, 
intensity NR.
4 weeks 
group then 2 
months 
home PFMT
3 individual + 20 
group
Pages 2001 PFMT+BF NA 1 1 group session, individual 
BF training 15 mins, 5/
week/4 weeks. Home: 10 
reps, 4 sets, 5 times/week
NR BF vaginal 
pressure. Clinic 
only
15 min sessions Supine 
10 reps/4 sets
4 weeks 
individual 
then 2 
months 
home PFMT
23 individual
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Parkkinen 2004 
PFMT+ES+BF+VW
NA 1 Short, low-intensity, 8–10 
reps. High intensity: 5s/
10s, 5 reps, low intensity: 
20–30s/40–60s, 5 reps, 
supine & standing. 
Contract & cough. Home: 
2 sets/day, 5 days/week
High intensity 1. BF vag EMG
2. ES 
interferential 5–
10 mins 50 Hz, 
5–10 mins 10–
50 Hz Clinic 
only. 3. VW
1. BF
2. ES 10 mins
3. VW (20–80 g), 30 
min/day, 5 days/week, 
during daily activities
Weekly to 
one year. 
Duration 
individual-
ised: 'until 
desired 
outcome 
achieved'
9 (3–29)
Parkkinen 2004 
PFMT+VW
NA 1 a/a a/a VW VW (20–80 g), 30 min/
day, 5 days/week, 
during daily activities
12 months. 3
Pieber 1995 PFMT+BF NA 1,2 Perineal 
ultrasound
Contract-relax times NR. 
100 PFX per day. 
Encouraged to do the 
'knack'. Individualised 
home program
Intensity NR. 
Relaxation of 
abdominals, 
gluteals, thighs
BF: Perineal 
ultra-sound (3 
times). Clinic 
only
BF: Visualised PF on 
screen (3 sessions)
3 months 2–4 weekly 
intervals, 3 
(asses ment)
Pieber 1995 
PFMT+BF+VW
NA 1 a/a a/a 1. BF: Perineal 
ultra-sound. 
Clinic only
2. VW
1. Visualised PF on 
screen (3 sessions)
2. VW (20–70 g) 15 
mins during daily 
activities
3 months a/a
Sung 2000 PFMT Explanation, no 
treatment
NR PFM exercises 'as 
developed by Bo', details 
NR. Exercises in clinic 
with video. Home: same 
exercises, details NR
Intensive 6 weeks 6
Turkan 2005 PFMT+ES NA 2 (not clearly 
reported)
5s contractions, 10 reps, 5 
sets/day, 5 sets added in 
each week. Home: also 
with activities of daily 
living, provocation
Maximum 
intensity
ES -
Interferential, 4 
vacuum 
electrodes 
Clinic only
10 mins each 0–10 Hz, 
0–100 Hz. Voluntary 
contractions with ES
5 weeks 15
Wong 2001 PFMT+BF NA NR Home: NR Fast: maximal 
Slow: as long as 
possible.
BF vag EMG 5 sets: 'fast'/10s rest: 3 
reps, 'slow'/1 min rest: 
2 reps. with BF. Clinic 
only
4 weeks 4
Wong 2001 PFMT+BF+ 
abdominal EMG BF
NA NR a/a a/a BF vag EMG & 
EMG BF-rectus 
abdominis 
Clinic only
a/a with abdominal 
EMG BF to minimise 
rectus activity
4 weeks 4
PFMT = pelvic floor muscle training, PFX = pelvic floor exercises, BF = biofeedback, ES = electrical stimulation, VW = vaginal weights EMG = electromyography, vag = vaginal, reps= repetitions, NA 
= not applicable, NR = not reported, a/a = as above
Table 11: Summary of interventions (Continued)BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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5). Rates of cure from 22% [49] to 80% [36] and rates of
cure/improvement from 86% [49] to 100% [36,48] were
reported. The highest quality study using BF demon-
strated a cure rate of 58% (provocative pad test) and of
62% (48 hour pad test) for women training at home with
pressure BF [47]. A combined rate of 97% cured/
improved was reported (self-report). There was no statis-
tical difference in the outcomes of women in the other
arm of this study performing an identical intensive PFMT
program over 6 months without BF. Four studies using
vaginal EMG BF as a clinic treatment showed cure rates
from 25–80% [32,36,38,42] or positive and statistically
significant outcomes [50].
Regarding the use of EMG BF on the abdominal wall, one
study found no difference in outcome with the addition
of abdominal wall BF to reduce rectus abdominis activity
[50]. Another also used surface EMG to reduce abdominal
muscle activity [44], but the heterogeneity among the pro-
tocols and lack of information about electrode placement
precluded conclusions about its value. There was also
insufficient evidence from this review about the role of
ultrasound to teach or train a PFM contraction in order to
make any recommendations.
One study reported that no subjects underwent surgery
during the study period [49]. Another reported that 3/48
(6%) of women proceeded to surgery after unsuccessful
treatment [47]. There were no reports of the occurrence of
adverse events [42,47-49].
When considering all the studies on PFMT/BF, a total of
25/29 (86%) incontinence outcomes were positive and
statistically significant, while four outcomes failed to
show significant change after treatment. All of these
occurred in two studies [44,50] with treatment times of 4
and 6 weeks respectively. Non-significant results may
have been due to measurement error, as pad tests without
demonstrated reliability were used [44,50] and because of
the short duration of training, which may have been insuf-
ficient to effect physiological changes. Type II error should
also be considered when interpreting these results as one
study [50] gave no evidence of a power calculation to
ensure sufficient numbers to demonstrate a treatment
effect. Thus, in summary, there is strong evidence from a
number of RCTs that PFMT with vaginal EMG or pressure
BF is effective for the treatment of SUI, but it may be no
more effective than PFMT alone.
Table 12: Summary of outcome measures used according to ICS recommendations, need for surgery, side effects
Studies C1 C2 C3 C4 C5 % subjects proceeding to 
surgery
No serious adverse events 
reported
Aksac (2003) 1 1 1
Arvonen (2001) 1 1 1
Balmforth (2004) 1 1 2
Berghmans (1996) 1 2 1 1
Bidmead (2002) 1 1 1
Bo (1999) 3 3 1 1 yes
Bo (2000) 1
Cammu & van Nylen (1998) 2 3 1 1 17 yes
Chen (1999) 2 1 yes
Dumoulin (1995) 1 1 1
Dumoulin (2004) 1 1 1 2 yes
Finkenhagen (1998) 1
Glavind (1996) 1 1 yes
Hay-Smith (2002) 1 2
Johnson (2001) 1 2 1
Knight (1998) 1 1 1
Miller (1998) 1
Morkved (2002) 2 2 1 1 4.3–6.3 yes
Pages (2001) 1 1
Parkkinen (2004) 1 1 1 10.5 yes
Pieber (1995) 1 0
Sung (2000) 1
Turkan (2005) 1 3 1
Wong (2001) 1 2 1 1
ICS Outcome Measurement categories; C 1= patient symptoms: perception of cure/improvement; C 2 = quantification of symptoms (objective 
measures): pad use, diary of incontinent episodes, pad tests; C 3 = clinicians' measures (pelvic floor muscle measures); C 4 = quality of life 
measures; C 5 = socioeconomic measures, blank cells indicate no relevant report.BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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1.3 PFMT with ES
There was evidence from one level II study (quality score
43%) [39] for a treatment effect using a combination of
PFMT/ES, although no cure rates were reported. No differ-
ence between groups was found when home treatment
with vaginal ES was added to a 14 week PFMT program,
but there were positive and significant within-group dif-
ferences for PFMT/ES based on objective and quality of
life measures. This study was only available as an abstract,
thus the potential exclusion of useful information may
have contributed to the poor quality score. When includ-
ing the non-RCTs, all measures of incontinence (6/6)
showed positive and statistically significant change after
treatment. One study [54] reported no adverse events.
Thus there is limited evidence from one RCT that PFMT
combined with vaginal ES is an effective intervention for
women with SUI, but it may be no more effective than
PFMT alone.
1.4 PFMT with VW
One level II study (quality score: 65%)[37] and one level
III-2 study [51](quality score: 74%) provided evidence
about PFMT combined with vaginal weights (Table 7).
Arvonen (2000) reported cure rates of 50% (pad test) and
22% (subjective report) and cure/improvement rate of
61%. This study compared women training the PFM with
and without VW, but with a different training protocol for
each group. Across both studies, all measures of inconti-
nence (100%) showed positive and statistically significant
change after treatment.
One study [37] reported no pain associated with using VW
and a dropout rate of 12%. The other study [51] reported
that four subjects proceeded to surgery for their inconti-
nence during the study period.
There is evidence from one RCT that PFMT with vaginal
weights may be effective in improving the outcomes for
women with SUI. However, from this review, it is not pos-
sible to comment whether PFMT with VW is more effec-
tive than the same PFMT protocol performed without VW.
Table 13: Definitions of 'cure' and 'improvement'
Definitions of cure Studies Definitions of Improvement Studies
Less than 1 g loss on pad test Parkkinen (2004), Dumoulin (1995) Decrease of 50% or more in pad weight Aksac (2003)
1 g or less on pad test Aksac (2003)
Glavind (1996)
Self-report of less urine loss compared with 
pre-treatment
Pieber (1995)
Less that 2 g loss on pad test (st.b.vl) Dumoulin (2004)
Knight (1998)
Self-report: continent (cured), almost 
continent (improved) (5 point Likert scale)
Bo (1999)
2 g or less on stress test (st.b.vl) Bo (1999)
Morkved (2002)
Rare or minor incontinence on exertion & 
'satisfied'
Chen (1999)
Self-report: unproblematic (5 point Likert 
scale)
Bo (1999)
Morkved (2002)
Decrease of > 50% in IE & decrease in 
'symptoms'
Pages (2001)
'No incontinence' (measure NR) & no 
incontinence on UDS
Chen (1999) Greatly improved: >75% improvement on 
pad test
Knight (1998)
No incontinence for 7 days Johnson (2001)
No urine loss on any occasion & negative 
stress test
Pieber (1995)
No urine loss on paper towel test Miller (1998)
IE = incontinent episodes, st.b.vl. = standardised bladder volume, UDS = urodynamic studies
Summary of incontinence outcomes for different combina- tions of physical therapy Figure 1
Summary of incontinence outcomes for different 
combinations of physical therapy. Total number of posi-
tive and statistically significant measures of incontinence 
(black) and non-significant measures of incontinence (grey) 
for different combinations of physical therapy. Included are 
subjective, objective and quality of life measures. PFMT = pel-
vic floor muscle training. PFMT+BF = pelvic floor muscle 
training with biofeedback. PFMT+BF+ES = pelvic floor mus-
cle training with biofeedback and electrical stimulation. 
PFMT+ES = pelvic floor muscle training and electrical stimu-
lation. PFMT+VW = pelvic floor muscle training with vaginal 
weights. PFMT +BF+ES+VW = pelvic floor muscle training 
with biofeedback, electrical stimulation and vaginal weights. 
PFMT+BF+VW = pelvic floor muscle training with biofeed-
back and vaginal weights.
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1.5 PFMT with BF/ES
One level II study (quality score: 91%) [41] with two arms
using the same combination of PFMT with vaginal EMG
BF/ES, one arm with the addition of an abdominal muscle
training program, showed cure rates of 70% & 73%
respectively and a cure/improvement rate of 90% in both
arms. A further level II study (quality score: 83%) [45],
using two different types of ES ('low' intensity at 10 Hz
and 'high' intensity at 35 Hz) in combination with PFMT/
BF, reported combined cure/improvement of 67% when
based on intention to treat. A level IV study (quality score
68%) [56] used a combination of PFMT with vaginal pres-
sure BF and interferential currents for ES (Table 8). Over-
all, 20 different incontinence measures were reported, all
exhibiting positive and statistically significant change.
When assessing the effect of adding ES to PFMT/BF, one
study found no statistically significant difference in pad
test results or PFM strength between groups, suggesting no
additional benefit [45]. However, as no power calculation
was reported, these results should be interpreted with cau-
tion because of the possibility of insufficient subject num-
bers.
There were no reports of adverse events and no statements
were made regarding surgical intervention. However, one
study reported women withdrawing from home treatment
with ES because of discomfort [45].
Thus there is good evidence from two level II studies that
PFMT combined with BF and ES is effective treatment for
women with persistent postnatal SUI and also for older
women up to the age of 68 years. Due to the heterogeneity
in the protocols, it is not possible to identify which com-
ponents of the programs contributed to their efficacy.
1.6 PFMT with BF/VW
One level II study (quality score 57%)[49], using this
combination of therapies, was identified for this review
(Table 9). Trans-perineal ultrasound was used to provide
BF to identify and reinforce a correct elevating contraction
of the PFM at three clinic visits, with PFMT including VW
for home training. The reported cure rate was 39%, the
combined cure/improvement rate was 85%, but no clini-
cal outcomes were reported in terms of statistical signifi-
cance. There is thus limited evidence from one level II
study for this combination of treatments.
1.7 PFMT with BF/ES/VW
No level II studies were identified but one level III-2 study
(quality score 74%)[51] included in this review had a
treatment protocol with PFMT, BF, ES and VW (Table 10).
Cure rates at the end of the 12 month study period were
not reported but both measures of outcome showed pos-
itive and statistically significant change after treatment.
Outcomes were reported at 5 years but there was co-inter-
vention and contamination of the treatment groups after
12 months which precluded group analysis. Thus there is
only limited evidence from one non-RCT for this combi-
nation of treatment.
Three studies involving ES which considered adverse
events reported none with combined PFMT/ES
[41,51,54].
1.8 Length of follow up
Follow-up after the end of the treatment program was
reported by two RCTs [42,45] and two non-RCTs [51,54]
in this review. One RCT suggested that urine loss on pad
testing was reduced between end of intensive treatment
and 6 month follow-up all in groups but statistically sig-
nificant differences were not reported [45]. The other RCT
assessed women after 4 weeks of treatment, again two
months later and after 30 months by postal question-
naire. Women who had trained with BF were reported to
have better continence status than women performing
PFMT without BF [42]. Of the two non-RCTs, one evalu-
ated women four more times over 21 months after three
months of a PFMT/ES program [54]. Declining success
over this time was reported, corresponding with decline in
PFM exercise compliance. The other study suggested
ongoing benefit 5 years after a combined PFMT/VW pro-
gram [51]. However, the results of studies of lower meth-
odological quality should be interpreted with caution.
2. What is the evidence for different types of PFMT?
Strength training
The recommended exercise dosage for strength training of
the PFM has been extrapolated from exercise physiology
principles for normal skeletal muscle. Slow velocity, near
maximal contractions, sustained for 6–8 seconds, with 3
sets of 8–12 contractions performed 2–4 days a week and
continuing for up to 5 months, are recommended [10,16].
• Effect of strength training on incontinence outcomes
Three level II studies [34,44,47], one level III-3 [33] and
one level IV study [55] investigated a training protocol
with maximum sustained PFM contractions as the only
type of PFMT. Some women trained with BF [44,47]. The
duration of the training period varied from 6 weeks
[33,44] to 6 months [34,40,47,55]. All but one [44] were
otherwise based on a similar exercise dosage in terms of
the intensity, number of repetitions and frequency of
training, as recommended by Bo (2004)[10]. All the stud-
ies required the women to train daily at home. However,
there were differences in the protocols: two studies had an
additional weekly group session over 6 months [34,55],
where another had weekly or fortnightly therapist contact
over 6 months but without group training [47].BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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The reported efficacy of these strength training protocols
from the two high quality studies (quality score >90%)
was 44% & 56% [34] and 58% & 40% [47] in terms of the
number of subjects cured by objective and subjective
measures respectively at 6 months. Rates of cure/improve-
ment were higher: 48% [34] and 93% [47] but were based
on different self-rated assessment scales, which may partly
explain the discrepancy in outcome. One RCT [44]
reported 38% of subjects subjectively cured at 6 weeks.
There is evidence from two high quality level II studies
that PFMT according to strength training principles is
effective in relieving the symptoms of SUI in women.
Change in symptoms may be noted after six weeks. Effec-
tive outcomes were achieved with either additional regu-
lar group training or individual sessions with the
physiotherapist.
• Effect of strength training on PFM strength
Possibly the most valid and reliable measure of PFM
strength was reported by Dumoulin (2004) using a
dynamometer. Although changes in incontinence were
demonstrated after 8 weeks of PFMT with clinic-based BF/
ES, there were no statistically significant increases in PFM
strength in either arm of this study. Other studies reported
PFM strength changes using perineometry
[33,34,36,44,45,47,48,50], which may be a reliable but
not necessarily valid measure due to influences of intra-
abdominal pressure [62]. One RCT showed an increase in
PFM strength after 4 weeks of PFMT [50] and another after
3 months [47]. Three RCTs demonstrated increased
strength after 6 months of an intensive strength training
protocol [34,45,47]. One showed incremental increase
between 0–3 and 3–6 months [45]. Some training was
done with BF [44,45,47,50]. One RCT demonstrated
strength changes after 6 weeks of submaximal PFMT [44],
an intensity which has been shown to increase muscle
strength in untrained individuals [10]. However, no data
was provided about prior PFMT in the subjects to substan-
tiate this in the study population.
One study used perineal ultrasound to demonstrate a sta-
tistically significant elevation of the bladder neck position
after PFMT for three different conditions: at rest, with
maximum Valsalva, and maximum contraction [53]. Two
RCTs [36,37] reported PFM strength changes using digital
assessment but this measure has doubtful reliability for
scientific purposes [62].
In summary, there is strong evidence from a number of
high quality RCTs that using a specific strength training
protocol increases PFM strength, with measurable
changes between 4 weeks and 6 months. However, in
accordance with physiological principles [10], evidence
from this review confirmed that longer training times pro-
duce greater gains in strength.
Skill training
In terms of PFMT, skill training implies the acquisition of
a higher level motor skill in timing a PFM contraction just
prior to the event which provokes urine loss. This
approach to PFMT has been variously called motor learn-
ing, motor re-learning, the 'knack', functional training
and counter-bracing [10].
Two RCTs investigated the effect of teaching women with
SUI to contract the PFM just prior to a rise in intra-abdom-
inal pressure [43,46]. One tested women after one week of
practising the 'Knack' of contracting the PFM before a
cough, with reported cure rates of 23% (with a deep
cough) and 75% (with a moderate cough) [46]. The other
study reported 7% of subjects cured and 47% cured/
improved, using a more complex functional training pro-
tocol, although details were not reported [43]. This study
reported no difference between two groups training with
a skill training protocol and with combined strength and
skill training. However, the authors attributed the non-
significant result to type II error.
Nine other studies included some aspects of skill training
as part of their PFMT protocol, but details of the actual
training process and the exercise dosage were poorly
reported [32,37,38,41,48,49,51-53].
While there is increasing evidence that skill training may
be an important component of a PFMT protocol, there
was insufficient information provided about the specific
exercises performed to recommend any particular
approach to skill training.
Combination strength & skill training
Six studies were identified which included both maxi-
mum intensity contractions and elements of skill training
in their PFMT protocols [37,41,43,51-53]. Three of these
were RCTs with very different treatment protocols and
outcomes [37,41,43]. Dumoulin (2004), with the short-
est duration of 8 weeks training and weekly contact for
training with the physical therapist, had the highest
reported cure rate (73%). Arvonen (2000) reported 50%
cure using strength training as well as vaginal weights for
additional skill training during physical activities. Evi-
dence from these studies suggests that a combination of
strength and skill training is effective treatment for SUI
but the contribution of each component to the outcome
is unclear.
Role of abdominal muscles
Dumoulin (2004) investigated the effect of adding spe-
cific deep abdominal muscle training to a combinedBMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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PFMT/BF/ES program and found that it conferred no sta-
tistically significant benefit. By contrast, Wong (2001)
investigated the effect of reducing activity of the rectus
abdominis during PFMT using surface abdominal EMG
BF but found no benefit with objective measures.
Four other studies in this review [32,36,44,49], specifi-
cally trained relaxation of the deep abdominal muscles,
while one other stated that training of the deep abdomi-
nal muscles was included in weekly group sessions [34].
However, the different methods of assessing outcome and
multiple other confounding variables do not allow con-
clusions to be drawn from these results.
In summary, thus there is evidence from one high quality
RCT study to suggest that the addition of deep abdominal
muscle training confers no additional benefit for women
performing a combined PFMT/BF/ES program.
3. What other reported factors could affect outcome of physical 
therapy?
Age
Women from age 18 to 84 were included in the 24 studies
in this review, suggesting that women of all ages can be
expected to respond to physical therapy. There was evi-
dence from high quality RCTs for specific training pro-
grams for young women [41] and mid-aged women
[34,47]. One study showed that skill training was effective
in older women [46] but evidence is lacking for other spe-
cific physical therapy programs specifically for older
women.
Initial severity of incontinence
Not all studies reported initial severity of incontinence
symptoms but in those which did, two different measures
were used: number of incontinence episodes per day
[34,38,44,54] or week [32,50] and the volume of urine
lost on pad test [34,36-47,50,52-54,56]. Due to the differ-
ences in pad test methodology it was not possible to make
direct comparisons between populations at baseline.
A number of the RCTs stratified women to the treatment
groups to remove the confounding effect of severity of
baseline symptoms of incontinence, although none
reported subgroup results. However, one study found that
women with more mild symptoms of SUI responded bet-
ter (88% cure) to the same treatment program than
women with severe symptoms, none of whom were cured
[52]. Although women in that study were not randomised
but assigned to groups according to severity of symptoms,
baseline variables of age and BMI, which could have been
confounders, were not statistically significantly different
between groups.
Compliance with the training program
The effectiveness of an exercise program can only be eval-
uated if it is known how well the subjects complied with
the prescribed home program. Seven studies in this review
reported on subject compliance with the treatment proto-
col [34,39-41,45,54,56]. In all cases but two [45,54] it was
reported that a diary was kept. One study found that com-
pliance with the home PFMT protocol predicted a success-
ful outcome [54]. Three studies [34,39,45] reported the
actual level of subjects' compliance. In groups with only
PFMT as a home program, it was reported that 75% [39]
to 93% [34] of subjects were compliant. One study
reported that subjects performing a home PFMT program
with daily pressure BF over 6 months were compliant with
the program 75% of the time, while only 48% were com-
pliant when home ES was added to the home treatment
program [43]. Another study reported good or excellent
compliance by 45% of subjects when combining ES with
PFMT in a home program [39].
In summary, compliance with the training program was
not routinely reported. Despite the lack of a standardised
approach to assess and report compliance, it appears that
compliance may be greatest if a home program does not
include BF or ES.
Initial pelvic floor muscle strength
Although all studies reported teaching women to contract
the PFM correctly prior to commencing a PFMT program
only one stated that all women were actually able to do so
[48]. One study included women who were initially una-
ble to contract their PFM but did not report numbers of
affected women or the effect of this on the outcome [42].
Turkan (2005) assigned subjects to three groups according
to severity of incontinence by pad test results and reported
significantly lower PFM strength in the women with most
severe incontinence (>10 g on pad test) before treatment.
Even though no women were cured after treatment in the
most severely affected group, this group had the greatest
response to treatment in terms of changes in PFM strength
and leakage on pad test. Similarly, Knight (1998) reported
that initially lower PFM strength on perineometry was
correlated with greater improvement in continence out-
comes.
4. What is the evidence for the optimal period of treatment and 
number of treatments?
Duration of treatment period
Parkkinen (2004) reported a mean of 9 (3–29) weekly
treatments with subjects ceasing treatment when a
'desired outcome' was achieved. All the other studies had
a treatment protocol with a predetermined training period
and number of contacts with the therapist. The length of
treatment varied from one week [46] to 24 months [54].BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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Number of treatments
The number of treatments varied from two [46] to 30
[34,40]. The number of treatments was not stated in two
studies [39,53] but was standardised in all other studies
except Parkkinen et al (2004). Instruction was provided in
groups as well as individually (see Table 11 for details).
Response time
One study [46] showed a change in incontinence status
after only one week using a skill training approach, while
another [56] reported changes after 3 weeks. Nine studies,
all reporting positive and statistically significant change in
symptoms, had training periods from 4–8 weeks 9
[33,36,38,41,42,44,48,50,52], while others ranged from
3–6 months [32,34,37,39,40,43,45,47-49,53-55]. From
this review it is not possible to determine if there is an
optimal length of treatment period or number of treat-
ments. However, one level III study showed that women
respond at different rates to the same treatment protocol
[52].
5. What is the evidence for the effectiveness of physical therapy in 
the clinical setting?
Only one study stated specifically that the intervention
was performed in a physiotherapy clinic in a primary
health care setting [55]. This level IV study found that
67% of subjects with SUI were cured/improved after six
months of PFMT with a trained physiotherapist, suggest-
ing that outcomes in clinical practice may comparable
with those of RCTs.
Generalisability of findings to clinical practice settings
There was little information provided in the studies
reviewed about factors relevant to determination of the
generalisability of the study findings, for example, the set-
ting where the treatment took place, the source popula-
tion for patients or how the patients were selected. In
eight studies [37,38,45,48-52], treatment was conducted
in a hospital or university outpatient clinic but in 14 stud-
ies location was not stated. One was a multi-centre study
but the settings were not identified [34]. The profession of
the person performing the treatment was stated in 19
studies (all physiotherapists) but it was not clearly stated
in the other five studies [33,36,42,44,46].
Discussion
This systematic review reports the evidence of physical
therapy interventions for SUI from full text studies or
abstracts published in English during the last decade.
Despite suggestions that the methodological quality of
studies has increased over time, no correlation was found
between a more recent date of publication and the quality
score of the studies published over the last 10 years and
included in this review. Thus it must be acknowledged
that high quality studies published prior to 1995 may
have been missed by the limitations on publication date
which were set.
The inclusion of both RCTs and non-RCTs dictated the
presentation of results as a narrative summary. The meth-
odological quality of the studies was variable, with some
RCTs being of lower quality than the lower level studies.
This provides a dilemma for systematic reviewers, as
restriction of study inclusion to RCTs is considered to
ensure identification of high quality studies [20,63].
However, the possibility of well-designed cohort studies
providing less biased evidence than poorly designed RCTs
has been documented [64]. It is acknowledged that the
methodological quality of the critical review tools them-
selves may have incorrectly reflected the quality and rank-
ing of the included studies [65].
One of the aims of this review was to investigate outcomes
relevant to clinical practice. To this end, level III and IV
studies, not previously reported in systematic reviews of
the literature on SUI, were included. The inclusion of
these studies with lower levels of evidence provided infor-
mation about aspects of physical therapy not obtainable
from the RCTs reviewed, for example, about the different
response rate and the effectiveness of treatment in the pri-
mary care setting.
Question 1: What is the evidence for PFMT, either alone or 
in combination with adjunctive therapies, when 
considering all treatment protocols, for the treatment for 
SUI in women, immediately and up to 12 months after 
treatment?
This review found consistent evidence from high quality
level II studies for PFMT alone and in combination with
adjunctive therapies in the treatment of SUI. Further evi-
dence is presented about the efficacy of PFM strength
training, in support of previous reports [14,16]. New evi-
dence is provided for the efficacy of different combina-
tions of PFMT with BF and ES but the combination of
PFMT with BF was shown to be no more effective than
PFMT alone. It is unclear specifically how the combina-
tions of therapy contribute to the outcome of any training
program and whether it is more effective to administer
adjunctive therapies in the clinic setting or home environ-
ment.
All of the studies reviewed demonstrated positive treat-
ment effects for physical therapy, despite a range of train-
ing protocols and combinations of adjunctive therapies.
Studies with a lower quality score have a greater potential
for bias and, with the plethora of different outcome meas-
ures used, it was not possible to directly compare the
effectiveness of the different protocols. Four papers were
only available as abstracts so that the assessment of meth-BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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odological quality in these studies may be underestimated
due to the limited information available.
Factors not assessed by the studies which could affect outcome
This review found that physical therapy is effective in the
treatment of SUI. However, there were other factors, com-
mon to all studies, which may have contributed to the dif-
ferences in outcome. The expertise of health professionals
may vary and also the quantity and quality of the educa-
tional information about the condition and PFM func-
tion. The impact of these factors on the outcome of
treatment has yet to be evaluated. Furthermore, it has
been well documented that many women depress the
PFM instead of contracting it in a cephalad direction after
brief verbal or written instruction [66,67]. Thus assess-
ment for correct action by vaginal examination should be
considered a prerequisite for commencing a PFMT pro-
gram. However, correct action was not always reported
and several studies used other methods (vaginal EMG or
pressure BF) which are not considered to be valid assess-
ment tools [62]. Two studies used perineal ultrasound,
which has demonstrated reliability but is not a readily
available clinical tool [62]. However, the reliability of any
method will be dependent on the experience and exper-
tise of the user and the results should be interpreted with
this in mind [68].
Outcome measures
The plethora of outcome measures reported in the
included studies also contributed to the difference in
results and constrained comparisons between studies.
Outcomes measures have been reported here in terms of
their positive and statistically significant findings and also
reported in terms of the recommended ICS categories. It
was notable that outcomes were reported under every ICS
category except socio-economic outcomes. Previous sys-
tematic reviews [14,16] have noted the absence of reports
on socio-economic outcomes. This review substantiates
this finding for the past decade.
Not all studies reported their outcomes in terms of the
number of subjects 'cured' or 'improved', although this
would seem to be an important consideration in determi-
nation of the clinical effectiveness of any intervention for
this condition. Moreover the definition of 'cure' has not
been agreed. Different methods of evaluating 'cure' eg by
pad test and self-report resulted in different outcomes.
This difference may be explained by the fact that women,
who are provoked to leak during a stress test which
involves vigorous jumping, but who do not normally
engage in jumping, may report satisfaction with treatment
outcome. This might suggest that patient self-report and
satisfaction with treatment are possibly more relevant
measures. However, very different cure rates are obtained
if women are asked to report if they are continent (as
opposed to 'almost continent') or if their incontinence is
'unproblematic'. This language difference possibly
accounted for the considerable difference in cure/
improvement for two otherwise similar PFM strength
training programs. The use of common, standardised self-
report questionnaires is recommended in research and
clinical practice by the ICS, and if utilised, will facilitate
interpretation and comparison of future studies.
Reported cure rates were much lower than the percentages
of women 'cured & improved'. This was also noted by
Hay-Smith et al (2001). If the small percentages of
women seeking surgical treatment after physical therapy
for SUI are considered as a measure of success, then it
would seem that the greater measure of effect, 'cured &
improved', may be a more valid expression of women's
satisfaction with the outcome. However a validated, ICS-
approved satisfaction score is currently lacking.
There was little evidence about outcomes in the medium
term up to 12 months after the completion of treatment.
It was not the aim of this review to consider the longer
term outcomes of physical therapy. However, outcomes in
the short, medium and longer term are important infor-
mation, both for consumers and for the calculation of the
economic benefits of physical therapy particularly when
compared with alternative treatments.
Question 2: What is the evidence for different types of 
PFMT?
There is strong evidence from a number of high quality
RCTs for specific strength training of the PFM in effecting
change in continence status, underpinning its theoretical
rationale and confirming previous reports [14,16]. There
is evidence that PFM strength continues to increase over
six months with specific strength training. Changes in
bladder neck position as a result of PFMT have been dem-
onstrated, suggesting structural changes in the PFM. How-
ever, the optimal training protocol is less clear as different
approaches were effective. Thus the addition of weekly
group exercises or individual sessions with the therapist
may not be essential components of the training per se
but rather the training effect may be enhanced through
regular therapist contact for motivation.
Despite the number of studies including skill training in
the PFMT protocol, its contribution in effecting change in
health outcomes was not clear. There was considerable
heterogeneity among the treatment and training proto-
cols, precluding determination of clear conclusions. How-
ever, from the review, it appears there is sufficient weight
of evidence to recommend a combination of strength and
skill training in the treatment of SUI.BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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It should be remembered that only studies of PFMT for
women with SUI were included in this review. It was not
the aim of this review to consider the evidence of all the
available literature on the effect of PFMT on different
parameters of PFM function such as strength, endurance
or skill level for women with other types of PFM dysfunc-
tion or for asymptomatic women. Therefore the effects of
the PFMT protocols described may not be shown in other
populations of women, particularly in those with other
dysfunctions of the PFM such as prolapse and bowel
incontinence.
This review found very different approaches to training
the abdominal wall muscles in conjunction with the pel-
vic floor. There were no trials where deep abdominal
training alone was performed as an intervention for SUI.
However, the outcomes of an effective PFMT program
were not improved by the addition of deep abdominal
muscle training, nor by reduction of rectus abdominis
activity by surface EMG BF.
The evidence from this review, that there is no benefit in
adding BF, ES or deep abdominal muscle training to a
PFMT program, should be considered from a clinical per-
spective. There may have been subgroups of women with
different characteristics who responded differently to the
treatment protocol but who were not identified in the
analysis. In clinical practice, patients have different char-
acteristics which will demand a reasoned approach to the
choice of treatment at any one time. Thus it cannot be
assumed that additional deep abdominal muscle training
may not be useful for selected women with SUI who have
demonstrated weakness of their deep abdominal muscles
or that BF may not be beneficial for some women with
poor proprioception of their pelvic floor or low motiva-
tion to exercise. It seems vital for the clinician to consider
all relevant clinical findings (eg age, baseline pelvic floor
muscle strength, proprioception, motivation, general
physical fitness) when deciding on the best treatment for
any one patient.
Question 3: What other reported factors could affect 
outcome of physical therapy?
Age
This review found evidence for PFMT with and without
adjunctive therapies for women up to the age of 84 who
suffer SUI. There was evidence from a number of RCTs for
the efficacy of a specific training program with PFMT, BF
and ES for younger women after childbirth. There were a
number of RCTs with consistent reports of efficacy of PFM
strength training in women of mid-age, but limited evi-
dence for specific PFMT protocols for older women. Given
the demographics in the western world with increasing
numbers of women living longer and the known associa-
tion of incontinence with increasing age, effective training
programs for older women are needed.
Initial severity of incontinence
Previous studies have reported conflicting findings about
the effect of initial incontinence severity on the outcome
of treatment [14,16]. The results of this review suggest that
although fewer women with more severe symptoms may
be cured by physical therapy, there may nevertheless be a
significant improvement in their symptoms. Whether
women with more severe SUI require longer treatment,
different PFMT protocols or different combinations of
therapy remains to be determined.
Compliance with the home training program
Another factor which may influence outcome is the degree
to which subjects actually comply with the treatment pro-
gram prescribed. Compliance with PFMT is a complex
issue and has been the subject of a previous review [69].
The terminology is not agreed as some authors consider
'adherence' to be a more appropriate term implying vol-
untary co-operation rather than coercion [69,70]. Subject
compliance or adherence was infrequently and generally
poorly reported with no standardised, validated or relia-
ble approach to its assessment. However it would appear
to be of considerable importance in any PFMT program
which depends on subjects performing exercise in order to
effect physiological changes. There are complex psycho-
social issues involved in interventions which demand that
women commit time and effort on a regular basis to train-
ing [69,70]. It is likely in the high quality studies with
good outcomes that subjects adhered to the treatment
protocol. However, in studies which reported poorer out-
comes and also did not report subjects' compliance, it is
not possible to say whether an ineffective intervention or
the subjects' lack of compliance was responsible for the
poor result.
Initial PFM strength
There was evidence from two studies suggesting that
women with weaker PFMs had a greater improvement in
continence symptoms than women with stronger PFM.
Previous reviews have reported conflicting findings
[14,15]. There were no reports of what strategies were
used if women were unable to contract the PFM at all,
even though this would be likely to have an adverse effect
on outcome.
Question 4: What is the evidence for the optimal period of 
treatment and number of treatments?
We found evidence for the efficacy of shorter treatment
protocols than the 4–6 months recommended by the ICS.
The basis of the ICS recommendation was to allow time
for an increase in PFM hypertrophy and volume as essen-
tial processes for increasing muscle strength. However,BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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this review has shown that treatment programmes of less
than three months may result in improved continence sta-
tus as well as increased PFM strength. Whether the combi-
nation of PFMT with adjunctive therapy or the actual
exercise dosage is the critical factor is unclear. The optimal
length of treatment and the number of treatment episodes
could be useful information for the marketing of physical
therapy for SUI. Some women may be deterred from start-
ing a physical therapy program if told that it is necessary
to commit to six months of intensive training with weekly
classes in order to become dry. This could be the focus of
future research as it seems important information for con-
sumers not only because of the implications for their time
commitment and motivation but also because of the cost.
More precise information about the length of treatment
and frequency of therapist contact would underpin eco-
nomic evaluations of conservative treatment which are
currently lacking.
Question 5: What is the evidence for the effectiveness of 
physical therapy in clinical practice settings and can the 
findings in the research settings be generalised to clinical 
practice?
This review sought to determine the effectiveness of phys-
ical therapy in the clinical practice setting where treatment
is administered to a regular clinical population by conti-
nence practitioners. Only one study clearly took place in a
clinical practice setting but as the inclusion criteria were
not stated in the abstract, it was not possible to identify
the characteristics of the study population. However, it
appears that PFMT conducted in a primary care setting
may be effective for the treatment of SUI.
The other studies in the review were considered for the
generalisability of their findings to clinical practice by
identifying the patient populations from which the study
samples were drawn, the types of settings in which treat-
ment was carried out and the health professional perform-
ing the treatment. However, this information was
generally poorly reported so that only limited conclusions
can be drawn.
Physiotherapists were the only health professionals stated
to be performing the treatment (in 83% studies), and
while continence training can be assumed for the thera-
pists in these studies, the level of expertise is likely to be a
key factor in determining success. Expertise in continence
management is likely to be a more important factor influ-
encing outcome in studies of clinical practice and should
be considered a pre-requisite for health professionals
treating SUI.
The effect of selection bias should also be considered in
this context. Bias is potentially introduced when a study
population consists of volunteers, who may be particu-
larly motivated and compliant. Volunteers may be well
motivated to succeed, particularly in studies requiring
commitment to a daily exercise program over a lengthy
period of time. Thus the outcomes of studies with a sam-
ple of volunteers may overestimate the true treatment
effect. All three of the highest quality studies had study
populations consisting at least partly of volunteers. In
clinical practice, women referred for treatment may be
variable in their enthusiasm about committing to a
lengthy exercise program. Thus there may be some limita-
tions to the generalisability of the results of RCTs recruit-
ing volunteers and this should be considered by clinicians
when interpreting the results.
Conclusion
Implications for practice
• There was strong evidence that PFMT alone, with BF and
with ES/BF is effective for women with SUI, with expected
rates of cure up to 73% and cure/improvement up to 97%.
• There was strong evidence for strength training of the
PFM to reduce symptoms of SUI and to improve PFM
strength.
• Changes in incontinence outcomes were demonstrated
after treatment duration of one week to six months, but
improvements in PFM strength may require at least 3
months of specific strength training.
• No benefit was found in this review in adding BF, ES or
abdominal muscle training to a PFMT protocol. However,
it is likely that these interventions still have a place in clin-
ical practice as adjuncts to PFMT in particular populations
of women.
• Strength PFMT protocols were effective in younger and
mid-aged women, but there was scant evidence on
strength training in older women.
• Evidence for skill training was found, especially if com-
bined with strength training in women of all ages, but the
optimal specific training protocol for skill training is
unclear.
• Women with different severity of symptoms and initial
PFM strength require different training programs and pro-
tocols. Women with weaker initial PFM strength and
more severe symptoms may have the greatest percentage
improvement in symptoms.
• Subjects using BF or ES as home treatment may be less
compliant with a treatment program than women per-
forming PFMT alone.BMC Women's Health 2006, 6:11 http://www.biomedcentral.com/1472-6874/6/11
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• No serious adverse events have been reported with phys-
ical therapy.
Implications for research
Research is needed into:
• economic outcomes as none have been reported
• the effectiveness of physical therapy in routine clinical
practice settings
• the external validity of RCTs. Future studies should more
adequately describe the setting for the intervention, exper-
tise of person delivering the treatment, the source and
characteristics of subjects
• the longer term outcomes of physical therapies
• programs and protocols appropriate for different sub-
groups of women eg women of different ages and with dif-
ferent severity of incontinence
• the factors which influence a subject's likelihood of
attending appointments, continuing with treatment and
complying with the home training program
• the optimal length of an episode of care
• a more standardised approach to outcome measurement
in research with appropriate outcome measures reflecting
clinical practice requirements
• an optimal minimum set of common outcome meas-
ures relevant to research and clinical practice settings
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